Home › Products › Oncology › Inflitza 25mg Capsule
Inflitza 25mg Capsule
Salt Composition: MIDOSTAURIN
- Manufacturer: INTAS PHARMACEUTICALS LTD
- Pack Size: 4 CAPSULE(s) IN A STRIP
- Dosage Form: CAPSULE
- Strength: 25MG
- Prescription Required
- Storage: Store inflitza 25mg capsule at room temperature (25°C) keep the capsule away from the reach of children and pets. If you miss a dosage, take it as soon as you remember. If it is almost time for the next dose, skip the missing dose. Do not take a double dose to compensate for a missed dose.
₹3214.00₹4017.19
Inclusive of all taxes
Product Introduction
Inflitza 25mg capsule contains midostaurin, an anti-cancer medicine belonging to the class of tyrosine kinase inhibitors. It is used in combination with other chemotherapy medications to treat acute myeloid leukemia (AML) in adults with FLT3 gene defects. Acute myeloid leukaemia is a cancer that begins in myeloid cells, a type of white blood cell, where the body abnormally produces excess numbers of these cells. The medicine is also used in adults to treat aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN), or mast cell leukaemia (MCL).
Do not take Inflitza capsule if you are allergic to midostaurin or any other ingredients in this medicine. Inform your healthcare professional if you have any symptoms of infection, heart disorder, lung problems, or breathing difficulties. If you experience any of the following symptoms after taking the medicine—fever, sore throat, mouth ulcers, cough with or without sputum, chest pain, difficulty breathing, or body swelling—report them immediately to your doctor.
This medicine is not recommended for children and adolescents below 18 years of age. Inform your physician if you are pregnant, breastfeeding, or planning pregnancy before starting therapy. Inflitza 25mg capsule may reduce fertility in both men and women; discuss this with your doctor before beginning treatment.
The most common side effects of this medicine are fever with reduced blood cell counts, nausea, vomiting, headache, musculoskeletal pain, increased blood glucose levels, and respiratory tract infection.
Uses
Inflitza capsule uses: Acute myeloid leukemia (AML) Aggressive systemic mastocytosis (ASM) Systemic mastocytosis with associated hematological neoplasm (SM-AHN) Mast cell leukemia (MCL)
How it works
Inflitza 25mg capsule is a kinase inhibitor that potently inhibits multiple receptor tyrosine kinases. It blocks the action of the kinases in the abnormal cells that express FLT3 mutant genes and stops their division and growth.
How to Use
Your doctor will decide the dose and duration of the treatment based on your disease condition, severity, and other factors. Take the inflitza 25mg capsule as prescribed by your doctor. Do not open, break, crush, or chew the capsules. Swallow the capsule whole with a glass of water. Take the capsules with food at the same time each day.
Side Effects
Inflitza 25mg Capsule side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Inflitza 25mg side effects are Serious Heart failure GI bleeding Fever with decreased blood cell counts Hypersensitivity reactions Kidney problems Pneumonia Blood infection Common: Swelling in the lower limbs Skin rash Increased blood sugar levels Abdominal pain Constipation, diarrhea Nausea, vomiting Musculoskeletal pain Headache Bleeding from nose Upper respiratory infection Tiredness Fever
References
- Rydapt 25 mg soft capsules - Summary of Product Characteristics (SmPC) - (EMC). www.medicines.org.uk. [revised on 2022] [cited 2023 Apr 13]. Available from: https://www.medicines.org.uk/emc/product/9134/smpc
- Highlights Of Prescribing Information - Inflitza 25mg capsule, [revised on 2017] [cited 2023 Apr 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf
- Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilmanâs Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.
Safety Advice
Pregnancy: unsafe Inflitza 25mg capsule is unsafe to administer in pregnant women because it may cause birth defects. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using effective contraception during the treatment and for at least 4 months after your last dose is necessary.
Lungs: Consult your doctor It is unknown whether inflitza 25mg capsule can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking inflitza 25mg capsule because the medicine passes into the breast milk in small amounts and may harm the baby.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.